Lemildipine is a 1,4-dihydropyridine calcium channel blocker which is under phase III development by Banyu (Merck and Co), in Japan, for its potential to treat hypertension and cerebrovascular ischemia. In one study, involving five patients with essential hypertension accompanied by cerebrovascular disorder, lemildipine, administered orally at doses of 5 to 20 mg/day, significantly lowered blood pressure and increased cerebral blood flow [256721]. Another study in 31 patients with essential hypertension demonstrated that lemildipine has significant pressure lowering effects without affecting serum lipids [256722]. Worldwide rights to market the drug have been assigned to Kowa in Japan.

01 Jan 1998·Hypertension ResearchQ3 · MEDICINE

Effects of Lemildipine, a New Calcium Channel Blocker, on Renal Microcirculation in SHR.

Q3 · MEDICINE

Article

Author: Tetsuya Ogawa ; Masahiko Kawabata ; Toshikazu Takabatake

The effects of lemildipine, a new dihydropyridine calcium channel blocker, on renal hemodynamics and the tubuloglomerular feedback (TGF) mechanism were examined in anesthetized 9- to 10-wk-old spontaneously hypertensive rats (SHR). Lemildipine, 3 micrograms.kg-1 i.v., did not reduce mean blood pressure (MBP) but tended to increase GFR and increased urinary excretion of sodium (UNaV). Filtration fraction (FF) and fractional excretion of sodium (FENa) remained unaltered. An additional dose of lemildipine, 9 micrograms.kg-1 i.v., reduced MBP and renal vascular resistance. Renal plasma flow tended to increase, and GFR was unchanged. FF significantly fell. UNaV and FENa remained at the control level. Micropuncture experiments revealed that the maximal reduction in proximal stop-flow pressure (SFP), an index of glomerular capillary hydrostatic pressure (Pgc), induced by perfusion of the loop of Henle was significantly reduced by high-dose treatment (8.8 +/- 1.3 vs. 13.7 +/- 1.9 mmHg in control). A high dose of lemildipine induced a rightward and slightly upward shift of the TGF curve; the steady-state tubular flow rate (V1/2) was increased, the maximal slope of the curve decreased, and SFP at V1/2 unaltered. A low dose of lemildipine did not affect TGF response. These results indicate that lemildipine attenuates the TGF response in SHR by dilating afferent arterioles and thereby corrects the left and downward shift of the TGF curve in SHR. In addition, the fall in FF indicates lemildipine-induced efferent arteriolar vasodilatation. Through balanced systemic and glomerular vasodilatation, lemildipine maintains the levels of Pgc and GFR in the face of reduced renal perfusion pressure.

01 Nov 1996·Arzneimittel-Forschung

Stereo-selective calcium antagonistic and binding properties of the enantiomers of lemildipine in vascular tissue of pigs and dogs.

Article

Author: Fukuta, Y ; Tanaka, Y ; Nakazawa, T ; Nakayama, K

Stereo-selective calcium antagonistic properties of the enantiomers of lemildipine (CAS 94739-29-4, NB-818) were assessed in vascular tissues, including pig coronary artery and dog cerebral artery. Ca2+ antagonistic action of (-)-lemildipine was about 5 times and 100 times more potent than nifedipine and (+)-lemildipine, respectively. (-), (+), and (+/-)-lemildipine showed a slow onset and long duration of Ca2+ antagonistic action. Pretreatment with (-)-lemildipine and (+/-)-lemildipine for 30 min inhibited the contractions produced by 5-hydroxytryptamine and endothelin-1 with pD2 values between 6.0-8.5, whereas (+)-lemildipine and nifedipine were less potent. Of the lemildipine enantiomers, (+)-lemildipine at a low concentration (1 nmol/l) had a slight but significant Ca2+ agonistic action. However, (+)-lemildipine had no apparent effect on the pCa-tension relationship in the dog basilar artery permeabilized with Staphylococcus aureus alpha-toxin. Enantiomers of lemildipine as well as nifedipine competitively antagonized the specific binding of (+)-[3H]PN 200-110 (isradipine) to the membranes of pig coronary artery in the following order: (-)-lemildipine > nifedipine > (+/-)-lemildipine > (+)-lemildipine. These results suggest that the stereo-selective Ca2+ antagonistic actions of lemildipine enantiomers and nifedipine assessed in the functional experiments were well correlated with their potencies for the competition with the (+)-[3H]PN 200-110 binding to the pig coronary artery.

100 Deals associated with Lemildipine

External Link

KEGG	Wiki	ATC	Drug Bank
D01151	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertension	Phase 3	-	Kowa Co., Ltd.	-
Hypertension	Phase 3	JP	-	-
Hypertension	Phase 3	-	Merck Sharp & Dohme Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis